Enrolling Clinical Trials

  • Principal Investigator

    Sahil A. Parikh, MD
    The purpose of this study is to deterimine if the Drug-Coated Chocolate Touch Balloon Catheters is safe and effective compared to a drug-coated balloon that is already approved in patients with a blockage in the blood vessels of their leg.
  • Principal Investigator

    Robert J. Sommer, MD
    This study has been designed to treat patients with a pulmonary conduit or valve that has a large amount of regurgitation or is too narrow and needs to be replaced.
  • Principal Investigator

    Ajay J. Kirtane, MD, SM
    The study has been designed to demonstrate the efficacy and safety of the Paradise Renal Denervation System when treating patients with high blood pressure known as hypertension. When blood pressure is persistently elevated and pushes against the walls of the artery over a long period of time it is known to cause Hypertension. The Paradise Renal Denervation System will be used in this renal denervation procedure to treat hypertension that can not be controlled by medication. It works by by disabling the arterial nerves and lowering blood pressure.
  • Principal Investigator

    Martin B. Leon, MD
    This is designed for patients with severe, symptomatic mitral regurgitation who are not candidates for conventional mitral repair.
  • Principal Investigator

    Susheel K. Kodali, MD
    Study for subjects with moderate-to-severe or severe functional mitral regurgitation (MR) and you have been determined to have symptoms due to heart failure despite being treated with currently available therapies, and are not an appropriate candidate for mitral valve surgery.
  • Principal Investigator

    Sahil A. Parikh, MD
    This study is for patients who suffer from a condition where one of the blood vessels that deliver blood to your leg has a significant narrowing. This is called peripheral artery disease (PAD). The narrowing may be suitable for a treatment technique called balloon angioplasty. One of the therapies that has been used to treat PAD is balloon angioplasty. It is a procedure where a small balloon is inserted into the blood vessel next to the area that is narrowed and inflated temporarily.
  • Principal Investigator

    Martin B. Leon, MD
    The purpose of this study is to evaluate a new device to treat patients who may benefit from the repair of their mitral heart valve due to mitral regurgitation. The device is called the Edwards Cardioband System (Edwards Cardioband System or the device). The device is investigational in the United States but has been approved in Europe. This clinical study is expected to take approximately 5 years to complete if you are eligible. You will need to return to your doctors office at 1 month, 6 months, and 1, 2, 3, 4 and 5 years after the device implant procedure.
  • Principal Investigator

    Susheel K. Kodali, MD
    The study is to determine whether aortic valve replacement is helpful for patients who have severe, calcific, aortic stenosis (a narrowing of the aortic heart valve, where calcium has attached to the valve surface, resulting in obstructed blood flow) and do not have symptoms.
  • Principal Investigator

    Robert J. Sommer, MD
    The Amulet IDE trial is a prospective, randomized, multi-center active control worldwide trial, designed to evaluate the safety and effectiveness of the AMPLATZER Amulet Left Atrial Appendage Occluder. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device (treatment) or a Boston Scientific WATCHMAN LAA closure device (Control). The trial will be conducted at up to 150 sites worldwide. All enrolled subjects will follow the protocol-required tests and assessments at each scheduled follow-up visit.
  • Principal Investigator

    Anthony L. Pucillo, MD, FACC
    This clinical trial is for patients diagnosed with carotid artery stenosis that are at high risk of a stroke. Carotid artery stenosis develops as a result of plaque buildup in the carotid artery. Over time plaque buildup creates a narrowing of the carotid artery, restricting the flow of blood. Thus, increasing the risk of stroke. In this research study the Roadsaver and the Nanoparasol systems will be used to treat carotid artery stenosis.
  • Principal Investigator

    Susheel K. Kodali, MD
    This research study is for patients with severe aortic stenosis. Patients may be considered for this study if they have a diseased aortic heart valve and who are at low operative risk for standard (traditional) open-heart surgery for aortic valve replacement (TAVR).
  • Principal Investigator

    Martin B. Leon, MD
    This is a multicenter, prospective randomized study to determine the safety and efficacy of the Watchman device in patients with irregular heart beat undergoing a less invasive procedure than open heart surgery called Transcatheter Aortic Valve Replacement (TAVR). In this procedure, an x-ray is used to visualize and guide the Watchman device via a catheter to replace the heart valve. This is done for patients with aortic stenosis (AS) where there is reduced blood flow, pain and fatigue because the blood has to work harder to pump blood due to narrowed valves in the blood vessels.
  • Principal Investigator

    Susheel K. Kodali, MD
    This is a research study designed to look at the safety and effectiveness of the TriGUARD 3 cerebral embolic protection device in patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of the study is to assess whether the TriGUARD 3 can prevent death, stroke, more subtle signs of brain injury, and/or silent brain injury as measured by a magnetic resonance imaging (MRI) study of the brain.
  • Principal Investigator

    Susheel K. Kodali, MD
    This is a research study to evaluate the use of a device to treat patients with Heart Failure (HF) whohave moderate aortic stenosis (AS). The Edwards SAPIEN 3 has already been approved by the FDA for usein patients who require an aortic valve replacement due to severe aortic stenosis. This is an international,multicenter, randomized, openlabel, clinical trial comparing the safety and effectiveness of TAVR(Transcatheter Aortic Valve Replacement) with the Edwards SAPIEN 3 THV (transcatheter heart valve) andmedical therapy to medical therapy alone in HF patients with moderate AS.